Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: A propensity score matching study
- PMID: 33004744
- DOI: 10.4103/jcrt.JCRT_380_19
Transarterial chemoembolization combined with microwave ablation versus microwave ablation only for Barcelona clinic liver cancer Stage B hepatocellular carcinoma: A propensity score matching study
Abstract
Purpose: We aimed to compare the outcomes of microwave ablation (MWA) alone with those of transarterial chemoembolization combined with MWA (TACE-MWA) for Barcelona clinic liver cancer (BCLC) Stage B hepatocellular carcinoma (HCC) and to identify the prognostic factors associated with the two treatments.
Materials and methods: This retrospective study was conducted in 150 BCLC Stage B HCC patients from April 2006 to November 2017. Of these, 88 patients were treated with MWA alone while 62 with TACE-MWA. Propensity score matching (PSM) was conducted to adjust for imbalances in clinical parameters. Procedure-related complications, local tumor progression (LTP), recurrence-free survival (RFS), and overall survival (OS) were analyzed.
Results: Before PSM, the maximal tumor diameters were 6.0 ± 1.0 cm and 6.7 ± 1.3 cm in the TACE-MWA and MWA groups, respectively, with a significant difference (P = 0.002); a significant difference was also detected in α-fetoprotein level (P = 0.013). After PSM, no difference was found in the two parameters (P = 0.067, 0.470). Before and after PSM, no difference was detected in the procedure-related complications (P = 0.803 vs. 1.000, P = 1.000 vs. 1.000), RFS (P = 0.786 vs. 0.689), and OS (P = 0.684 vs. 0.929). Tumor size and α-fetoprotein level were independent influencing factors for OS before and after PSM (P = 0.009, 0.023), while tumor size (D > 7) was an independent risk factor for poor OS (P = 0.011). Tumor number was an independent risk factor for RFS before and after PSM (P = 0.007 vs. P = 0.008). A significant difference was detected in LTP between the two groups with single tumor before and after PSM (P = 0.059 vs. P = 0.006).
Conclusions: The MWA alone group had RFS and OS comparable to that of the TACE-MWA group. TACE-MWA was effective in controlling LTP in patients with a single tumor.
Keywords: Hepatocellular carcinoma; microwave ablation; propensity score matching; transarterial chemoembolization.
Conflict of interest statement
None
Similar articles
-
Transarterial chemoembolization combined with microwave ablation and apatinib in patients with Barcelona clinic liver cancer Stage C hepatocellular carcinoma: A propensity score matching analysis.J Cancer Res Ther. 2020;16(2):250-257. doi: 10.4103/jcrt.JCRT_345_19. J Cancer Res Ther. 2020. PMID: 32474509
-
Comparison of the Efficacy and Prognostic Factors of Transarterial Chemoembolization Plus Microwave Ablation versus Transarterial Chemoembolization Alone in Patients with a Large Solitary or Multinodular Hepatocellular Carcinomas.Korean J Radiol. 2018 Mar-Apr;19(2):237-246. doi: 10.3348/kjr.2018.19.2.237. Epub 2018 Feb 22. Korean J Radiol. 2018. PMID: 29520181 Free PMC article.
-
CT-guided 125I brachytherapy for hepatocellular carcinoma in high-risk locations after transarterial chemoembolization combined with microwave ablation: a propensity score-matched study.Radiol Oncol. 2023 Mar 22;57(1):127-139. doi: 10.2478/raon-2023-0012. eCollection 2023 Mar 1. Radiol Oncol. 2023. PMID: 36942903 Free PMC article.
-
Combined radiofrequency ablation or microwave ablation with transarterial chemoembolization can increase efficiency in intermediate-stage hepatocellular carcinoma without more complication: a systematic review and meta-analysis.Int J Hyperthermia. 2022;39(1):455-465. doi: 10.1080/02656736.2022.2048095. Int J Hyperthermia. 2022. PMID: 35271786
-
The Combination Strategy of Transarterial Chemoembolization and Radiofrequency Ablation or Microwave Ablation against Hepatocellular Carcinoma.Anal Cell Pathol (Amst). 2019 Aug 26;2019:8619096. doi: 10.1155/2019/8619096. eCollection 2019. Anal Cell Pathol (Amst). 2019. PMID: 31534899 Free PMC article. Review.
Cited by
-
Locoregional Combined With Systemic Therapies for Advanced Hepatocellular Carcinoma: An Inevitable Trend of Rapid Development.Front Mol Biosci. 2021 Apr 13;8:635243. doi: 10.3389/fmolb.2021.635243. eCollection 2021. Front Mol Biosci. 2021. PMID: 33928118 Free PMC article. Review.
-
Combined treatments in hepatocellular carcinoma: Time to put them in the guidelines?World J Gastrointest Oncol. 2021 Dec 15;13(12):1896-1918. doi: 10.4251/wjgo.v13.i12.1896. World J Gastrointest Oncol. 2021. PMID: 35070032 Free PMC article. Review.
-
Comparison of Efficacy and Safety of TACE Combined with Microwave Ablation and TACE Combined with Cryoablation in the Treatment of Large Hepatocellular Carcinoma.Comput Intell Neurosci. 2022 Jun 25;2022:9783113. doi: 10.1155/2022/9783113. eCollection 2022. Comput Intell Neurosci. 2022. Retraction in: Comput Intell Neurosci. 2023 Nov 29;2023:9837201. doi: 10.1155/2023/9837201. PMID: 35795769 Free PMC article. Retracted.
-
Combination transarterial chemoembolization and microwave ablation vs. microwave ablation monotherapy for hepatocellular carcinomas greater than 3 cm: a comparative study.Diagn Interv Radiol. 2023 Nov 7;29(6):805-812. doi: 10.4274/dir.2023.232159. Epub 2023 Sep 4. Diagn Interv Radiol. 2023. PMID: 37665139 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous